Tyr p 2 is a 14-kDa protein classified under group 2 mite allergens. It is primarily found in the fecal pellets and cuticle of Tyrophagus putrescentiae, a storage mite species commonly associated with allergic sensitization in occupational and domestic settings . Unlike house dust mite allergens (e.g., Der p 2 or Der f 2), Tyr p 2 exhibits limited cross-reactivity with other group 2 allergens due to structural variations .
Prevalence: ~30–50% of storage mite–allergic patients show IgE reactivity to Tyr p 2 .
Epitope specificity: Unique surface residues (e.g., Asn114) reduce overlap with Der p 2–specific IgE epitopes, limiting cross-reactivity .
Monoclonal antibodies (mAbs): Murine mAbs targeting Der p 2 (e.g., 7A1) fail to bind Tyr p 2 due to substitutions at critical epitopes .
Human IgE: Sera from Dermatophagoides-sensitized patients show minimal IgE binding to Tyr p 2 .
Species-specific sensitization: Tyr p 2 antibodies are biomarkers for storage mite allergy but are not reliably detected by house dust mite allergen panels .
False negatives: Standard IgE tests for Der p 2/Der f 2 may miss Tyr p 2 sensitization .
Allergen-specific immunotherapy (AIT): Requires separate consideration due to low cross-reactivity with house dust mite allergens .
Hypoallergen design: Mutagenesis of surface residues (e.g., Asp114→Asn) could enhance diagnostic specificity .
Cross-Reactivity Analysis (2001):
Structural Modeling (2019):
ELISA: Recombinant Tyr p 2 is used in in-house assays for specific IgE quantification .
Component-resolved diagnostics (CRD): Includes Tyr p 2 in multiplex arrays for storage mite allergy profiling .
Functional role: The physiological function of Tyr p 2 in mites remains unclear, though homology to lipid-binding proteins (e.g., MD-2, NPC2) suggests a role in lipid transport .
Therapeutic targets: Engineered hypoallergens for AIT are under investigation but face challenges due to low natural immunogenicity .